LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 5 of 15: Mean cell count and mean growth rate across biological replicate 2. - Dataset (ID:20241)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | WZ-4-145 | 10.0 | uM | LJP6 | 72 | hr | 2543 | 1089 | 5578 | 0.1952 | -0.4792 |
| SK-BR-3 | XMD16-144 | 10.0 | uM | LJP5 | 72 | hr | 2543 | 1406 | 5578 | 0.2520 | -0.3748 |
| SK-BR-3 | Brivanib | 10.0 | uM | LJP5 | 72 | hr | 2543 | 5029 | 5578 | 0.9016 | 0.8191 |
| SK-BR-3 | Buparlisib | 10.0 | uM | LJP5 | 72 | hr | 2543 | 1222 | 5578 | 0.2191 | -0.4353 |
| SK-BR-3 | BX-912 | 10.0 | uM | LJP5 | 72 | hr | 2543 | 2154 | 5578 | 0.3861 | -0.1283 |
| SK-BR-3 | Canertinib | 10.0 | uM | LJP6 | 72 | hr | 2543 | 1508 | 5578 | 0.2704 | -0.3410 |
| SK-BR-3 | Celastrol | 10.0 | uM | LJP6 | 72 | hr | 2543 | 1765 | 5578 | 0.3164 | -0.2564 |
| SK-BR-3 | CGP60474 | 10.0 | uM | LJP5 | 72 | hr | 2543 | 1045 | 5578 | 0.1874 | -0.4936 |
| SK-BR-3 | CGP60474 | 10.0 | uM | LJP6 | 72 | hr | 2543 | 739 | 5578 | 0.1325 | -0.5945 |
| SK-BR-3 | CHIR-99021 | 10.0 | uM | LJP6 | 72 | hr | 2543 | 3443 | 5578 | 0.6172 | 0.2965 |
| SK-BR-3 | CP724714 | 10.0 | uM | LJP5 | 72 | hr | 2543 | 2063 | 5578 | 0.3698 | -0.1583 |
| SK-BR-3 | CP466722 | 10.0 | uM | LJP5 | 72 | hr | 2543 | 5693 | 5578 | 1.0206 | 1.0378 |
| SK-BR-3 | Crizotinib | 10.0 | uM | LJP5 | 72 | hr | 2543 | 1777 | 5578 | 0.3187 | -0.2523 |
| SK-BR-3 | Momelotinib | 10.0 | uM | LJP5 | 72 | hr | 2543 | 2779 | 5578 | 0.4982 | 0.0776 |
| SK-BR-3 | Dasatinib | 10.0 | uM | LJP5 | 72 | hr | 2543 | 2540 | 5578 | 0.4553 | -0.0011 |
| SK-BR-3 | Dasatinib | 10.0 | uM | LJP6 | 72 | hr | 2543 | 1353 | 5578 | 0.2426 | -0.3921 |
| SK-BR-3 | Dovitinib | 10.0 | uM | LJP5 | 72 | hr | 2543 | 2893 | 5578 | 0.5186 | 0.1153 |
| SK-BR-3 | Enzastaurin | 10.0 | uM | LJP5 | 72 | hr | 2543 | 6171 | 5578 | 1.1062 | 1.1952 |
| SK-BR-3 | Erlotinib | 10.0 | uM | LJP5 | 72 | hr | 2543 | 2664 | 5578 | 0.4776 | 0.0398 |
| SK-BR-3 | Foretinib | 10.0 | uM | LJP5 | 72 | hr | 2543 | 1898 | 5578 | 0.3403 | -0.2126 |
| SK-BR-3 | R406 | 10.0 | uM | LJP6 | 72 | hr | 2543 | 4380 | 5578 | 0.7851 | 0.6051 |
| SK-BR-3 | Pictilisib | 10.0 | uM | LJP6 | 72 | hr | 2543 | 1732 | 5578 | 0.3106 | -0.2671 |
| SK-BR-3 | Gefitinib | 10.0 | uM | LJP6 | 72 | hr | 2543 | 2224 | 5578 | 0.3987 | -0.1051 |
| SK-BR-3 | Geldanamycin | 10.0 | uM | LJP5 | 72 | hr | 2543 | 837 | 5578 | 0.1502 | -0.5620 |
| SK-BR-3 | Geldanamycin | 10.0 | uM | LJP6 | 72 | hr | 2543 | 1120 | 5578 | 0.2008 | -0.4690 |